A Point System to Forecast Hepatocellular Carcinoma Risk Before and After Treatment Among Persons with Chronic Hepatitis C

Dig Dis Sci. 2017 Nov;62(11):3221-3234. doi: 10.1007/s10620-017-4762-0. Epub 2017 Sep 30.

Abstract

Background: Risk of hepatocellular carcinoma (HCC) may be difficult to determine in the clinical setting.

Aim: Develop a scoring system to forecast HCC risk among patients with chronic hepatitis C.

Methods: Using data from the Chronic Hepatitis Cohort Study collected during 2005-2014, we derived HCC risk scores for males and females using an extended Cox model with aspartate aminotransferase-to-platelet ratio index (APRI) as a time-dependent variables and mean Kaplan-Meier survival functions from patient data at two study sites, and used data collected at two separate sites for external validation. For model calibration, we used the Greenwood-Nam-D'Agostino goodness-of-fit statistic to examine differences between predicted and observed risk.

Results: Of 12,469 patients (1628 with a history of sustained viral response [SVR]), 504 developed HCC; median follow-up was 6 years. Final predictors in the model included age, alcohol abuse, interferon-based treatment response, and APRI. Point values, ranging from -3 to 14 (males) and -3 to 12 (females), were established using hazard ratios of the predictors aligned with 1-, 3-, and 5-year Kaplan-Meier survival probabilities of HCC. Discriminatory capacity was high (c-index 0.82 males and 0.84 females) and external calibration demonstrated no differences between predicted and observed HCC risk for 1-, 3-, and 5-year forecasts among males (all p values >0.97) and for 3- and 5-year risk among females (all p values >0.87).

Conclusion: This scoring system, based on age, alcohol abuse history, treatment response, and APRI, can be used to forecast up to a 5-year risk of HCC among hepatitis C patients before and after SVR.

Keywords: Hepatitis C; Hepatocellular carcinoma; Prediction; Risk; Score.

Publication types

  • Multicenter Study
  • Validation Study

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Alcohol Drinking / adverse effects
  • Aspartate Aminotransferases / blood
  • Biomarkers / blood
  • Blood Platelets
  • Carcinoma, Hepatocellular / diagnosis
  • Carcinoma, Hepatocellular / virology*
  • Clinical Enzyme Tests
  • Decision Support Techniques*
  • Hepatitis C, Chronic / blood
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / diagnosis
  • Humans
  • Kaplan-Meier Estimate
  • Liver Neoplasms / diagnosis
  • Liver Neoplasms / virology*
  • Middle Aged
  • Platelet Count
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Reproducibility of Results
  • Risk Assessment
  • Risk Factors
  • Time Factors
  • United States
  • Young Adult

Substances

  • Biomarkers
  • Aspartate Aminotransferases